Pathomechanism of coagulation disorders in multiple myeloma (MM) patients is a complex one but most frequently connected with the presence of monoclonal protein. Until today the role of cancer procoagulant (CP) has not been studied in MM. In the paper CP activity in 26 patients with MM was tested. In 31% of patients elevated levels of CP activity above baseline was observed. Mean CP activity was higher in MM group than in control but without statistical significance. No major differences between mean CP activity in II and III stage of the disease MM type, and no correlation between CP activity and the concentration of monoclonal protein was seen. In none of the patients with CP activity above normal any thrombotic complications were observed.
|Original language||English (US)|
|Number of pages||7|
|Journal||Acta Haematologica Polonica|
|State||Published - Jan 1 2005|
- Cancer procoagulant
- Myeloma multiplex
ASJC Scopus subject areas